27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Pfizer Inc (NYSE:PFE) CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.
- Bourla speaking at JPMorgan's healthcare conference, said, "We are not in discussions. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."
- Related: New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows.
- Bourla said the company shipped thousands of Paxlovid courses in 2022 to China and, in the past couple of weeks, had increased that to millions.
- Concurrently, China's Healthcare Security Administration (NHSA) declined to include Paxlovid in a national reimbursement list that would have allowed patients to get it at a lower price throughout the country.
- Bourla added, "So they want it lower than the lowest of the middle, and we didn't agree. They are the second-highest economy in the world. And I don't think that they should pay less than Salvador, right, which is a poor country"..."We will continue with the private market in China, which is significant."
- Price Action: PFE shares are up 0.10% at $48.44 during the premarket session on the last check Tuesday.
- Photo via Company
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!